Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CAR T Cells, γδ T

Publication Date: December 25, 2025

Genetic engineering and allogeneic optimization of Vδ1 γδ CAR- T cells (ADI- 270) for cancer immunotherapy

This commentary examines how engineering strategies first developed in αβ CAR T cells can be adapted to Vδ1 γδ T cells, using the CD70-targeted, TGFβ-armored product ADI-270 as its case study. ADI-270 coexpresses a CD70 CAR and a dominant-negative TGFβRII to address the immunosuppressive tumor microenvironment and host-versus-graft rejection. In vitro, 20 ng/mL TGFβ1 impaired unarmored γδ T cells, whereas ADI-270 kept its proliferation and cytotoxicity. The authors also review passive and active cloaking approaches for allogeneic use, gene delivery routes such as RD114-pseudotyped γ-retroviral vectors and the TcBuster transposon (about 50% stable CAR integration, over 5,000-fold expansion…

Download Now →

Author: Wenlong Liu, Branden S Moriarity +1 more

Publications CAR T Cells G-Rex®100M, G-Rex®500M

Publication Date: December 20, 2025

SMART sensors for cell growth monitoring in closed system G-Rex® for scalable, cost-conscious cell and gene therapy manufacturing

A single-use resonant sensor built into the G-Rex® culture vessel (SMART G-Rex®), read wirelessly from outside, tracked T-cell expansion without opening the vessel. Four replicate sensors on one vessel showed a maximum coefficient of variation below 1.25%. Across 45 sensors seeded with 50 million activated cells from different donors, a final Skroot Growth Index above 7.08% indicated, with 99% confidence, more than 3.02 billion cells, a greater than 60-fold expansion. Scanning 11 vessels on the benchtop reader took 14 minutes 45 seconds, against 29 minutes 34 seconds for manual sampling. A harvest rule requiring SGI above 7% and a rate of change below 0.05 percentage points per hour flagg…

Download Now →

Author: Subhanwit Roy, Samuel Rothstein +12 more

Publications TCR T Cells G-Rex®100, G-Rex®24 Well Plate, G-Rex®6 Well Plate

Publication Date: December 17, 2025

Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation

Neoantigen-specific stimulation (NeoExpand) selectively expands TCR-engineered T cells and preserves less differentiated phenotypes better than the conventional rapid expansion protocol (REP). In 17 clinical infusion products, fewer than a quarter of cells carried both the engineered TCR and the matching CD4 or CD8 co-receptor, and REP lowered that frequency. NeoExpand using peptide-pulsed autologous PBMCs raised this fraction and gave more naïve/stem-like cells, but did not consistently raise total yield. Adding OKT3, with or without allogeneic feeders, produced exponential expansion, and IL-21 maintained a stem-like phenotype in CD8 cells. Across 35 TCR-donor pairs, PBMC with OKT3 or wi…

Download Now →

Author: Sanghyun P Kim, Noam Levin +14 more

Publications NK Cells

Publication Date: December 15, 2025

Non-viral TcBuster transposon engineering of CD70-CAR natural killer cells for the treatment of osteosarcoma

Armored CD70 CAR natural killer cells, built with the non-viral TcBuster transposon system and CRISPR/Cas9 knockout of CD70, delayed osteosarcoma growth and persisted in mice. In a tissue microarray of 40 patients, 32.5% of samples showed moderate to high CD70 staining, more often in higher-grade tumors. Healthy-donor peripheral blood NK cells were expanded on feeder cells and engineered with a CD70 CAR, soluble IL-15 and a TGF-β dominant-negative receptor. Edited cells averaged over 85% CD70 knockout and over 72% RQR8 expression. The full construct gave nearly 50% killing of 143B and SaOS-2 at a 1:32 ratio and, in an orthotopic 143B model, the longest survival and no lung metastases.

Download Now →

Author: Gabrielle M. Robbins, Jae-Woong Chang +14 more

Publications CAR T Cells

Publication Date: November 24, 2025

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

P-BCMA-ALLO1, an allogeneic anti-BCMA CAR-T product enriched in stem cell memory T cells, produced responses in heavily pretreated relapsed/refractory multiple myeloma when given after enhanced lymphodepletion. Across 27 research lots, the share of CD8+ Tscm cells correlated with tumor control in RPMI-8226 xenograft mice. In the phase I trial (NCT04960579), efficacy analysis covered 19 patients dosed at 2 × 10^6 cells/kg: response rates were 0% with cyclophosphamide 300 mg/m², 80% with 500 mg/m² and 83.3% with 1,000 mg/m². No patient needed bridging therapy, no dose-limiting toxicity or GvHD occurred, and no CRS exceeded grade 2. CAR-T cells expanded and shifted from Tscm toward effector…

Download Now →

Author: Hubert Tseng, Bhagirathbhai Dholaria +24 more

Publications TIL Cells

Publication Date: November 17, 2025

Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer

Expansion of tumor-infiltrating lymphocytes for adoptive cell therapy still follows the two-stage scheme of a Pre-REP phase and a rapid expansion phase, and this review surveys the modifications meant to make it faster, more robust and more functional. The classical rapid expansion runs about 14 days with IL-2, the anti-CD3 antibody OKT3 and irradiated feeder cells at a 200:1 ratio. Alternatives include IL-7, IL-15 and IL-21, genetically modified K562 feeder cells, neoantigen-selected TILs, CAR-TILs and CRISPR editing. Lifileucel reached an 80% disease control rate and 36% objective response rate in phase II melanoma trials and received FDA approval in 2024. Remaining obstacles include hi…

Download Now →

Author: Daniel Tovar Manzano, Nabil Subhi-Issa +9 more

Publications NK Cells

Publication Date: November 3, 2025

Pre-clinical characterization and process development of a BCMA-directed CAR NK-cell therapy product for relapsed/refractory multiple myeloma

Primary human NK cells from healthy donor blood, buffy coats and cord blood can be isolated, expanded and made to transiently express an anti-BCMA CAR without viral vectors or feeder cells. Serum-free medium, an IL2/IL15/IL21 cytokine mixture and nanoparticle-bound anti-CD2 and anti-NKp46 antibodies gave 30-40× expansion in 9 days. CAR mRNA delivered by lipid nanoparticles reached roughly 50-60% transfection efficiency, with good viability and surface CAR expression for up to 5 days. The CAR NK cells killed BCMA-expressing myeloma cell lines in vitro more strongly than untransfected NK cells, in a dose-dependent manner. Scale-up in G-Rex® bioreactors has begun, aiming for about 800 millio…

Download Now →

Author: Charles Yin, Angela Hamie +5 more

Publications CAR T Cells

Publication Date: November 3, 2025

Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma

A fully non-viral anti-BCMA CAR-T product was built by using CRISPR/Cas9 to insert the CAR at the TRAC locus with single-stranded DNA templates, combining a CD28 costimulatory domain with a 1XX-modified CD3ζ domain. Across manufacturing runs, knock-in efficiency ranged from 37.7% to 72.7%, with more than 99% TCR knockout. In mouse xenograft models of myeloma, the CD28-1XX cells cleared tumors, stayed tumor-free after repeated rechallenge, and outperformed CD28 wild-type CD3ζ and 41BB constructs. They also kept controlling tumor at 50,000 CAR+ cells per mouse, where constructs modeled on idecabtagene vicleucel and ciltacabtagene autoleucel relapsed. Off-target editing was limited to two lo…

Download Now →

Author: Alexis Talbot, Ke Li +26 more

Publications CAR T Cells G-Rex®6M Well Plate

Publication Date: November 3, 2025

Comparison of lentiviral promoters on the therapeutic efficacy of tri-specific CAR-T cells targeting CD19/CD20/CD22

A tri-specific CAR targeting CD19, CD20 and CD22 was built with either an EF1α or an MND promoter in the lentiviral vector, and both versions cleared Raji lymphoma cells in vitro and in a mouse model. At research scale, the MND vector gave higher CAR expression at a lower dose, while the EF1α version released more cytokine after tumor stimulation. With purified pre-clinical grade vector, MND gave the higher titer by dPCR, yet CAR-T performance was similar between the two. In NSG mice, MND CAR-T controlled tumor slightly more slowly, but all treated mice stayed tumor-free to the end of the study.

Download Now →

Author: Yang Liu, Borwyn Wang +13 more

Publications CAR T Cells

Publication Date: November 3, 2025

Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia

Autologous T cells carrying an anti-CD7 CAR together with a CD7 protein expression blocker, which prevents self-killing among the T cells, were given to two patients with relapsed or refractory CD7-positive acute myeloid leukemia. Products contained 1.0x10^9 and 2.4x10^9 CAR-T cells, and each patient received 1x10^6 cells/kg. The cells expanded strongly in blood, CD7-positive cells were undetectable by day 9, and both patients had grade 1 cytokine release syndrome and no neurotoxicity. Both reached MRD-negative remission, underwent allogeneic transplantation from matched unrelated donors, and were alive in continuous remission 13 and 4 months after infusion.

Download Now →

Author: Marco Becilli, Chiara Rosignoli +16 more

Publications NKT Cells G-Rex®6M Well Plate

Publication Date: October 13, 2025

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Cord-blood CD34+ stem cells engineered with an invariant NKT TCR, a mesothelin-specific CAR and secreted IL-15 yielded allogeneic CAR-NKT cells with strong activity against triple-negative breast cancer in preclinical models. Differentiated over a six-week culture, the product was more than 97% NKT TCR, CD3 and CAR positive and free of contaminating αβ T cells, with an average of 3–4 vector copies per cell. The cells killed tumor cells through CAR and NK-receptor pathways and eliminated CD1d-positive macrophages and myeloid-derived suppressor cells. In orthotopic mouse tumors, all treated mice cleared tumor and survived long term without graft-versus-host disease signs; in a metastatic mo…

Download Now →

Author: Yan-Ruide Li, Xinyuan Shen +12 more

Publications CAR T Cells, γδ T G-Rex®24 Well Plate

Publication Date: September 25, 2025

IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy

Co-culture of peripheral blood cells with irradiated K562 feeder cells expressing membrane-bound IL-21 and 100 U/mL IL-2 expands γδ T cells that are mainly Vδ1, and these cells kill ovarian and breast cancer cells. Vδ1 cells rose from a mean 6.14% before expansion to 70.20% after eight weeks, while Vδ2 cells fell to 3.79%. Expanded cells showed a higher activation status, controlled OVCAR8 ovarian tumor growth in NRG mice, and kept nutrient-receptor expression and metabolic function in patient ascites fluid. Electroporation with Cas9 and AAV6 delivery gave a HER2 CAR in 62% of cells, and CAR-armed Vδ1 cells produced the greatest tumor reduction in a SKOV3 xenograft model. Studies used hea…

Download Now →

Author: Ana L. Portillo, Misaal Mehboob +10 more